Stockreport

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vir Biotechnology, Inc.  (VIR) 
PDF - Phase 3 ECLIPSE registrational clinical program in chronic hepatitis delta on track to begin in the first half of 2025- Tobevibart and elebsiran in chronic hepatitis d [Read more]